UNSPSC 51342304: Entecavir

This classification denotes an antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5968Y6H45M. European Medicines Agency schedules Entecavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21468. Entecavir generally arises in the molecular formula C12H15N5O3.H2O. The term ENTECAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule entecavir under HS 29335995 and SITC 51576.

As of Q4 2014, ENTECAVIR remains the US FDA Preferred Term for this commodity. Entecavir bears US NLM identifiers UMLS ID C0971023 and NCI Concept Code C65513. SMILES: C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N.

UNSPSC 51342304 Entecavir is a Commodity code covering a specific antiviral pharmaceutical product, but the recent state and local procurement activity posted under this code does not reflect purchases of entecavir itself. Instead, the tagged opportunities name unrelated pharmaceutical products — doxycycline hyclate, ciprofloxacin hydrochloride, and naloxone — indicating a tagging mismatch between the code designation and the actual goods being procured. State and local procurement offices appear to use this code as a catch-all for pharmaceutical inventory and emergency medical supplies sourced through cooperative purchasing consortia and direct competitive bidding. The issuing bodies include state health departments and county governments purchasing for public health and community health initiatives.

Recent activity shows Illinois Department of Public Health procuring antibiotics through the MMCAP Infuse cooperative purchasing vehicle (awarded to Chartwell Rx LLC in August 2026 for $2,999,999.11 over the full contract term), and Seminole County, Florida issuing an IFB for naloxone and safe drug deactivation systems with quarterly deliveries (due July 26, 2023, though this posting predates current market conditions). The code sees activity in Florida and Illinois; the broader geographic concentration remains unclear from the limited recent opportunities. Vendors pursuing work under this code should note that cooperative purchasing piggyback arrangements and pharmaceutical warehousing contracts dominate the recent pipeline, and that the code's actual scope diverges significantly from its nominal product name, requiring careful review of each RFP, RFQ, or IFB to identify what is actually being purchased.